eFigure 2b. Post Randomization Insulin Use in EMPA-REG, LEADER and SUSTAIN-6.
Post-randomization use of insulin in the SGLT2-i or GLP-1 RA group compared to the placebo group.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.